Sandoz shutters formulations R&D unit, Indian generic plans intact
This article was originally published in Scrip
Executive Summary
Sandoz is to shutter its formulations R&D unit in India, its second such closure in less than a year, though the company has clarified that the move will not affect its plans to introduce generics in the country.
You may also be interested in...
Mylan Revamp Sees India R&D Layoffs; More In Store?
Mylan has handed pink slips to around 50 personnel at its Indian R&D unit as it pursues a global revamp aimed at streamlining operations and reining in costs following multiple acquisitions over the past few years.
Daiichi Closing Indian Site As Global Restructuring Continues
Daiichi Sankyo's decision to close an R&D facility in India has drawn mixed responses from the local industry, coming as it does against the backdrop of the Japanese firm’s disastrous acquisition of Ranbaxy.
Glenmark Divests API Company, Setting Out On Distinct Journeys
Glenmark Pharmaceuticals has divested its API arm to the Nirma group for over $681m, a move that will deleverage the drug maker’s balance sheet as it seeks to evolve into an “innovative/brand led organization.”